Key Takeaways
- Standalone revenue up 20%, EPS up 25%: The year delivered record turnover on strong domestic distribution demand and manufacturing volume gains, though Q4 exports softened on US tariff uncertainty.
- Distribution is the growth engine: The segment grew 29% in value and 10% in volume, driven by resorcinol, isophthalic acids and ethanolamine, with new product additions and strategic inventory planning sustaining momentum.
- Manufacturing margin dipped slightly but the turnaround is underway: Acrylamide solid sales improved manifold as Chinese import pricing rationalized, and capacity utilization gains plus operational efficiencies are lifting margins on NMA and acrylamide solids.
- Two new projects are in the pipeline but timelines are soft: A polyacrylamide solid commercial plant targets FY26-end or early FY27, while a feasibility study with Koei Chemicals for an amine facility is advanced but has no definitive timeline.
- What to watch next quarter: Whether merchant export volumes recover once US tariff policy clarifies, the pace of new customer additions in acrylamide solids and NMA, and any concrete update on the Koei Chemicals collaboration structure.
Distribution: The Quarter's Outperformance
- Broad-based domestic strength: The 29% value growth and 10% volume growth were led by sustained demand for resorcinol, isophthalic acids and ethanolamine, supported by strategic inventory planning and successful new product additions.
- Export drag was a Q4 story: Merchant export volumes dipped in Q4 specifically due to US market slowdown and tariff uncertainty; until Q3, exports were moving on a regular basis.
- Steady outlook despite local competition: Management expects local sales to remain steady even as local manufacturers emerge, citing reliability and fair pricing as the moat that keeps the company the supplier of choice, with new customer additions driving further growth.
- Tariff policy as a potential tailwind: The company is not currently impacted negatively by US tariff initiatives, and depending on how the US-China tariff war plays out, it may be able to capitalize on opportunities, though the tariff is on hold for 90 days.
Daga: "The only thing certain with Mr. Trump's policies is actually that it's really uncertain."
Manufacturing Margin Recovery
- Acrylamide solid inflection: In the latter part of the year, Chinese import pricing became much more rational due to a narrowing raw material cost gap in China, which helped stabilize and increase sales manifold; the company is now a supplier of choice for key domestic customers and is adding new export customers.
- Margin levers are operational, not pricing: Margin improvement on acrylamide solid and NMA comes from better capacity utilization and operational efficiencies in processes and energy cost, including use of renewable energy and agro-based fuel.
- Raw material tailwind emerging: Acrylonitrile was range-bound at $1,100–1,350/tonne during the year with a sudden dip in March; Q1 FY26 is seeing new capacity additions in China widen the supply-demand gap, which should help raw material procurement planning and drive profits further.
- Logistics unlocking export reach: Freight costs have come down significantly for certain key market areas, helping improve export reach and bringing back markets that were earlier unviable due to high freight cost.
- Polyacrylamide liquid headwind: The Morbi tile industry has been in a rough phase for one to two years; the company is working on a robust binder variant (BRILBIND CE03, already launched) and R&D is developing products for other applications like textiles.
Project Pipeline: PAM Solid and Amines
- Polyacrylamide solid commercial plant: The R&D process is finalized and equipment work is progressing stage by stage; the plant building at Jhagadia is already complete, which will shorten the commercial plant setup timeline. Commercial production is expected by FY26-end or Q1 FY27.
- Capex and funding: Total outlay is ₹60–100 cr, with all options open: internal accruals, debt or fresh equity; a definitive call will be taken at the opportune time.
- Koei Chemicals amine feasibility: A feasibility study is at an advanced stage for setting up an amine product manufacturing facility at the existing Jhagadia site; Koei will provide technology know-how and the company will set up the manufacturing unit. The mode of collaboration and marketing strategy are still under discussion and evaluation.
- No timeline commitment on amines: Management declined to give a definitive timeline for the feasibility report or the project itself, stating that only once feasibility is complete can timelines be provided.
- Capacity expansion flexibility: For acrylamide solid and NMA, the company has defined internal threshold limits for capacity utilization; when the time comes, capacities can be increased quickly and at very minimal cost because of the way the technology is set up.
Daga: "Now how that modus is and what the marketing strategy is going to be is something which is currently under discussion and evaluation. That's why it is kind of, you know, difficult to give a direct response to your query at this stage."
New Land, R&D and Strategic Positioning
- New land bank: Registration for a new parcel of land is nearing completion; it is a separate parcel, not defined for any particular project already in the pipeline, and will create a land bank for future projects.
- R&D facility operational: A new R&D facility was inaugurated earlier in May 2025 in New Bombay, taken on lease, housing the technology development and innovation team.
- Environment clearance progressing: The EC application is nearing completion and clearance is expected soon.
- Chinese dumping risk managed: The company has a policy of not participating in unfair pricing wars and is diversifying market outreach and adding new products to stay prepared.
Daga: "The new land is in a different place. It's a new parcel of land which as we mentioned earlier is being, you know, registered and acquired with a view to setting up future and upcoming projects. It's not defined for a particular project which is already in the pipeline."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Merchant export recovery | Volume uptick expected once US tariff policy becomes clearer and people adapt | From Q2 FY26 onwards |
| Polyacrylamide solid commercial production | Commercial plant ready; R&D process finalized, equipment work progressing | FY26-end or Q1 FY27 |
| Acrylamide solid and NMA capacity expansion | Capacities can be increased quickly at minimal cost when internal utilization thresholds are hit | No date; triggered by utilization |
| New product launches | Planned launches to improve market reach, top line and profitability | This year (FY26) |
| Environment clearance | Application nearing completion | "Soon" |
| New land registration | Registration process nearing completion | No date; "nearing completion" |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Standalone revenue | Highest ever, up ~21% YoY |
| Distribution revenue growth | 29% YoY in value, 10% YoY in volume |
| EPS growth | ~25% YoY |
| EBITDA margin | Improved YoY, driven by cost efficiency and product-mix optimization |
| PAT margin | Improved YoY |
| Debt-equity ratio | Very minimal |
| Return on equity | Rose YoY |
| Return on capital employed | Rose YoY |
| Distribution share of revenue | ~70% of top line |
| Domestic vs export sales mix | ~2/3 domestic, ~1/3 exports |
| Top 5 products concentration | 85% of top line, 82% of profit |
| Acrylonitrile price range | $1,100–$1,350/tonne during FY25, with a sudden dip in March |
| Acrylamide liquid capacity | 32,000 MTPA, of which 20,000 MTPA for merchant sales |
| Polyacrylamide liquids capacity | 40,000 MTPA |
| Acrylamide solid capacity | 3,600 MTPA |
| N-methylol acrylamide capacity | 2,000 MTPA |
| Polyacrylamide solids planned capacity | 10,000 MTPA initial |
| PAM solid project capex outlay | ₹60–100 cr ballpark |
| Amine project and land capex outlay | ~₹50 cr combined |
| Subsidiary operations status | Suspended from 30 January 2025 |